- Home
- SGMO vs PLX Comparison
SGMO vs PLX Comparison
Compare SGMO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- PLX
- Stock Information
- Founded
- SGMO 1995
- PLX 1993
- Country
- SGMO United States
- PLX United States
- Employees
- SGMO N/A
- PLX N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGMO Health Care
- PLX Health Care
- Exchange
- SGMO Nasdaq
- PLX Nasdaq
- Market Cap
- SGMO 122.8M
- PLX 127.4M
- IPO Year
- SGMO 2000
- PLX 1998
- Fundamental
- Price
- SGMO $0.54
- PLX $1.46
- Analyst Decision
- SGMO Buy
- PLX Strong Buy
- Analyst Count
- SGMO 6
- PLX 1
- Target Price
- SGMO $4.50
- PLX $15.00
- AVG Volume (30 Days)
- SGMO 5.7M
- PLX 622.1K
- Earning Date
- SGMO 08-12-2025
- PLX 08-13-2025
- Dividend Yield
- SGMO N/A
- PLX N/A
- EPS Growth
- SGMO N/A
- PLX N/A
- EPS
- SGMO N/A
- PLX 0.05
- Revenue
- SGMO $63,756,000.00
- PLX $59,764,000.00
- Revenue This Year
- SGMO $1.29
- PLX $65.02
- Revenue Next Year
- SGMO $1.60
- PLX $57.34
- P/E Ratio
- SGMO N/A
- PLX $30.11
- Revenue Growth
- SGMO 239.92
- PLX 0.18
- 52 Week Low
- SGMO $0.41
- PLX $0.82
- 52 Week High
- SGMO $3.18
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SGMO 50.80
- PLX 45.52
- Support Level
- SGMO $0.50
- PLX $1.46
- Resistance Level
- SGMO $0.70
- PLX $1.53
- Average True Range (ATR)
- SGMO 0.05
- PLX 0.06
- MACD
- SGMO 0.01
- PLX 0.01
- Stochastic Oscillator
- SGMO 29.17
- PLX 35.71
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.